United Therapeutics CEO sells 9,500 shares under plan
Rhea-AI Filing Summary
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 on July 21, 2026, acquiring 9,500 common shares, then sold 9,500 shares in multiple open-market trades at weighted-average prices between $523.81 and $537.13. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. Following this option exercise, a family trust holds 303,410 stock options, while Rothblatt also directly owns 40,513 common shares and has additional indirect holdings including 166 shares held by a spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.77M approx. pre-tax spread)
Exercise and Sale
18 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.06M)
Approx. gross sale proceeds
$5.06M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.77M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F16 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F3, F2 | 120 | $524.3664 | $63K |
| Sale | Common Stock F1, F4, F2 | 160 | $526.2375 | $84K |
| Sale | Common Stock F1, F2 | 240 | $527.46 | $127K |
| Sale | Common Stock F1, F5, F2 | 509 | $529.5507 | $270K |
| Sale | Common Stock F1, F6, F2 | 1,926 | $530.50 | $1.02M |
| Sale | Common Stock F1, F7, F2 | 2,605 | $531.5154 | $1.38M |
| Sale | Common Stock F1, F8, F2 | 360 | $532.4678 | $192K |
| Sale | Common Stock F1, F9, F2 | 640 | $533.5778 | $341K |
| Sale | Common Stock F1, F10, F2 | 1,760 | $534.6148 | $941K |
| Sale | Common Stock F1, F11, F2 | 341 | $535.442 | $183K |
| Sale | Common Stock F1, F12, F2 | 839 | $536.3742 | $450K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F13 | -- | -- | -- |
| holding | Common Stock F14 | -- | -- | -- |
| holding | Common Stock F15 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 303,410 contracts (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (16)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $534.17 to $535.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $535.24 to $536.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $536.36 to $537.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F14. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F15. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F16. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $523.81 to $524.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $525.875 to $526.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $528.99 to $529.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $530.01 to $531.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $531.015 to $531.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $532.03 to $533.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $533.08 to $533.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Stock options exercised: 9,500 shares
Exercise price: $135.42 per share
Shares sold: 9,500 shares
+5 more
8 metrics
Stock options exercised
9,500 shares
Options exercised on July 21, 2026 at $135.42 per share by a family trust
Exercise price
$135.42 per share
Strike price of the exercised stock options expiring March 15, 2027
Shares sold
9,500 shares
Common stock sold on July 21, 2026 in open-market transactions
Sale price range
$523.81–$537.13 per share
Price ranges across multiple trades as detailed in footnotes F3–F12
Options remaining in trust
303,410 options
Stock options held by a family trust after the 9,500-option exercise
Direct common shares
40,513 shares
Directly held United Therapeutics common stock reported as of July 21, 2026
Spouse-held shares
166 shares
Indirect ownership via spouse, shown in the holdings section
Plan option pool
1,734,410 stock options
Total options referenced in the Rule 10b5-1 plan footnote F1
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, family trusts, +1 more
5 terms
Rule 10b5-1 trading plan financial
"pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"exercise of stock options and sale of the resulting shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
indirect ownership financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did United Therapeutics (UTHR) report for CEO Martine Rothblatt?
United Therapeutics reported that a family trust for CEO Martine Rothblatt exercised 9,500 stock options at $135.42 and sold 9,500 common shares on July 21, 2026 in multiple open-market trades under a pre-arranged Rule 10b5-1 trading plan.
What stock options did the United Therapeutics (UTHR) CEO exercise in this filing?
A family trust for CEO Martine Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share on July 21, 2026. These options are part of a larger pool of up to 1,734,410 options expiring on March 15, 2027 referenced in a Rule 10b5-1 plan.
Were the UTHR insider transactions made under a Rule 10b5-1 plan?
Yes. The filing indicates the Rule 10b5-1 checkbox is marked and footnote F1 states the option exercise and resulting share sales were made pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, with specific termination conditions.
What holdings remain for the United Therapeutics (UTHR) CEO after these transactions?
After the reported exercise, a family trust holds 303,410 stock options expiring March 15, 2027. Separately, Martine Rothblatt directly owns 40,513 common shares and has additional indirect interests, including 166 shares held by a spouse and shares held in various family trusts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
